Telix receives AUD$17.25 million R&D tax refund
Filed with ASX · · 2 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
In the deck
Earlier from Telix Pharmaceuticals
- Leadership changes including Darren Smith appointment as CFO
- Illuccix Reimbursement Milestone and Launch Updates
- Appendix 4C and Activities Report for March 2022 quarter
- ProstACT TARGET Phase II Study Ethics Approval
- Telix Enters Licence Agreement with Lilly for Olaratumab
Later from Telix Pharmaceuticals
- Expansion of Partnership with RefleXion for Prostate Cancer
- Distribution Agreement with Isologic for Illuccix in Canada
- Zircon Kidney Cancer Imaging Study completes Enrollment
- Kevin Richardson appointed as CEO, Telix Americas
- Appendix 4C and Activities Report for June 2022 Quarter
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals